# Pizarra — PT-pseudo_47d8b39fd07f (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_47d8b39fd07f
Task: 1

Encounter: Urology - outpatient on 22 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 60-year-old male
  - PSA: 21.0 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.19 ng/mL²
  - PSA velocity: 5.99 ng/mL/yr
  - Prior PSA: 23.5 ng/mL
  - Prostate volume: 112.15 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.4009605 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, COPD
  - Problem list / PMHx: Hypertension, COPD
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 21 ng/mL. PI-RADS 3. PSAD 0.19. Prostate volume 112 mL. csPCa 0.40.

Vitals: weight 78 kg, height 186 cm, BMI 22.5, BP 140/82 mmHg, HR 74 bpm. Smoking: Non-smoker.

Chief complaint: Rising PSA trajectory combined with intermediate mpMRI findings warrants specialist review following a previously Negative biopsy.

History: The patient, a 60-year-old retired baker, initially presented for evaluation of PSA elevation in early 2022, with values climbing to 23.5 ng/mL before stabilizing at 21.0 ng/mL. He reports moderate lower urinary tract symptoms, chiefly nocturia and a weak stream, yielding an IPSS score of 17. A Non-smoker, his past medical history encompasses well-controlled hypertension and mild COPD, currently managed with amlodipine, valsartan, lisinopril, metoprolol, tiotropium, and salbutamol PRN. He maintains an active lifestyle, cycling to work five days weekly, and drinks roughly seven units of alcohol each week. Married, he resides in a multi-generational household with his wife and adult son, a setup he describes as highly supportive. Beyond urinary complaints, he notes stable right knee osteoarthritis that required six physiotherapy sessions last year, alongside occasional mild insomnia. He explicitly denies bone pain, haematuria, or unexplained weight loss. He has previously declined research study participation and wishes to maintain that position.

Physical examination: DRE: Normal exam. Prostate texture is symmetrically enlarged, smooth, and firm, lacking discrete nodules or asymmetry. General assessment remains unremarkable, recording blood pressure at 140/82 mmHg and heart rate at 74 bpm, with no peripheral lymphadenopathy or abdominal masses detected.

Patient info: retired baker; Married; Lives with adult child (multi-generational household).
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 7 units / week; exercise Cycling 5x/week (commuter); IPSS score: 17/35 (moderate LUTS).

Recent other appointments: GP practice nurse — flu vaccination; Physiotherapy — lower back, six sessions; Radiology — chest X-ray (routine).
Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.52 +/- 0.22   (95% CI 0.12-0.91)

Where the uncertainty comes from:
  - aleatoric  dA = 0.19  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 4.1 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=3.0, bx_ord=1.0, psa=21.0, age=60.0, psad=0.19, dre_ord=0.0, vol=112.15, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  1. PSA velocity (5.99 ng/mL/yr): This dynamic information is crucial for assessing the rate of change, which is a key driver in risk stratification, but was not used by the prior.
  2. mpMRI report details: The full prose of the mpMRI report is missing, which could clarify the PI-RADS 3 score (e.g., extent of lesion, features) and is vital for clinical context.
  3. PSA history trend: The prior only saw the current PSA (21.0) and prior PSA (23.5), but the full trend data (including the time course) is not explicitly detailed in the variables it read, which could indicate a more aggressive trajectory than implied by the single velocity number.

WHY THE SUGGESTION COULD BE WRONG
  1. Epistemic uncertainty: The prior is in a 'discuss' tier (0.52 +/- 0.22), meaning it genuinely cannot distinguish between biopsy and no biopsy based on the limited structured data it used.
  2. Contradiction potential: A PI-RADS 3 score combined with a rising PSA velocity (5.99 ng/mL/yr) might suggest a higher risk than the prior's statistical average suggests, especially given the prior negative biopsy status.
  3. Prior negative biopsy: The prior's model might not adequately weigh the significance of the prior negative biopsy result when assessing the current findings, potentially leading to an overestimation of the need for further investigation.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details high-risk features within the PI-RADS 3, it would increase the need for biopsy.
  <document> PSA history (trend / velocity beyond the headline value) -> If the trend shows a steeper rise or more concerning velocity, it would increase the need for biopsy.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the LUTS or any prior discussions about the PSA trajectory.
  <document> laboratory results (full panel) -> To check for any other relevant laboratory markers that might influence the decision.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_47d8b39fd07f", "radiology_report": "Subject: mpMRI Prostate | LUMC | 15 Jan 2025\n\nClinical Indication:\nAssessment of PSA trend (23.5 ng/mL in Feb 2024, now 21.0 ng/mL) after a prior Negative systematic biopsy.\n\nFINDINGS:\nGland measures 112.15 mL. T2 sequences show a 12 mm focus in the right mid-gland peripheral zone, showing intermediate signal with subtly indistinct borders. DWI indicates moderate restriction alongside moderately lowered ADC values. DCE highlights focal early enhancement. Seminal vesicles appear normal. Pelvic lymph nodes show no suspicious features. Extracapsular extension is absent.\n\nIMPRESSION:\nPI-RADS 3 lesion in the right mid-gland peripheral zone. Prostate volume 112.15 mL. PSAD 0.19 ng/mL/mL. csPCa predicted probability 0.4009605."}

  **psa_trend**
  {"case_id": "PT-pseudo_47d8b39fd07f", "psa_trend": [{"date": "Mar 2022", "val": 2.5}, {"date": "Feb 2023", "val": 6.9}, {"date": "Feb 2024", "val": 19.3}, {"date": "Jan 2025", "val": 21.0}]}

  **previous_notes**
  {"case_id": "PT-pseudo_47d8b39fd07f", "previous_notes": [{"date": "01 Aug 2023", "author": "Dr. R. van den Berg (GP)", "text": "01 Aug 2023 - Dr. R. van den Berg (GP): Routine follow-up captured PSA at 11.5 ng/mL. Moderate lower urinary tract symptoms are present, though haematuria and bone pain are denied. Urology referral for further workup and multiparametric MRI was arranged with patient consent."}, {"date": "27 May 2024", "author": "Dr. R. van den Berg (GP)", "text": "27 May 2024 - Dr. R. van den Berg (GP): Repeat testing shows PSA elevation to 23.5 ng/mL. LUMC imaging identified a PI-RADS 3 lesion, while the earlier systematic biopsy yielded Negative results. Urology re-evaluation was scheduled to review the imaging and laboratory data."}]}

  **laboratory_results**
  {"case_id": "PT-pseudo_47d8b39fd07f", "laboratory_results": [{"name": "PSA", "val": "21.0 ng/mL", "date": "09 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "3.22 ng/mL", "date": "09 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "15%", "date": "09 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "14.4 g/dL", "date": "09 Dec 2024", "flag": ""}, {"name": "WBC", "val": "5.7 x10^9/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "183 x10^9/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "88 umol/L", "date": "09 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "09 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "21.6 nmol/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "69 U/L", "date": "09 Dec 2024", "flag": ""}, {"name": "LDH", "val": "191 U/L", "date": "09 Dec 2024", "flag": ""}, {"name": "HbA1c", "val": "6.1 %", "date": "09 Dec 2024", "flag": ""}]}

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy suggests it is not necessary for this specific decision based on the other retrieved data.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 3 lesion in the right mid-gland peripheral zone
  PSA velocity of 5.99 ng/mL/yr (from trend data)
  Prior negative biopsy result

  AGAINST sampling this patient now:
  PI-RADS 3 score (which is intermediate risk)
  DRE findings: Normal

WHERE THIS LEANS
  The retrieved evidence presents a conflict: the imaging shows a PI-RADS 3 lesion, and the PSA velocity is concerning, which argues for sampling. However, the DRE is normal, and the prior biopsy was negative, which argues against immediate sampling. This leans towards a cautious approach, suggesting that the intermediate imaging finding and rising PSA velocity warrant further discussion, but the negative prior biopsy tempers the immediate need for intervention.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: borderline)

Deferring the biopsy is the recommended course given the conflict between the PI-RADS 3 finding and the prior negative biopsy. The evidence supporting sampling includes the PI-RADS 3 lesion and a rising PSA velocity of 5.99 ng/mL/yr, but this is tempered by the normal DRE and the prior negative result. The statistical prior suggested biopsy, but the retrieved evidence leans toward caution due to the intermediate risk score and lack of other high-risk features.

Variables that carried weight: age=noted, dre=noted, psa=important, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
